Drugs / YHP1604
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03116516 | Apr → May 2017 | hyperlipidemia, hypertensive disorder | Yuhan Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YHP1604 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03116516 ↗ |
| Route | Oral | “All subjects will receive a single oral dose of YHP1604 administered in the morning.” NCT03116516 ↗ |